New data
In announcing the guidelines today, the ACS says its updates are based on new evidence since 2010 that shows screening saves lives, and that advances in case management can avoid the concerning harms from overdiagnosis and overtreatment. For many men with prostate cancer, their cancer will never grow or cause harm in their lifetime, while treatment can run the risk of erectile dysfunction and urinary incontinence.
In the new guidance, the ACS adds guardrails, firstly advising all men to be informed about the risks and benefits. If a PSA test comes back high—defined as 3 ng/mL or higher for men under 70 and 6.5 ng/mL or higher
→ Continue reading at Ars Technica